Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
暂无分享，去创建一个
H. Goldschmidt | Shaji K. Kumar | T. Plesner | R. Orlowski | H. Nahi | P. Moreau | S. Basu | T. Facon | M. Qi | S. Usmani | C. Chiu | M. O'Dwyer | A. Perrot | C. Hulin | K. Weisel | N. Bahlis | T. Ahmadi | Jianping Wang | C. Uhlar | J. Mace | C. Venner | H. Quach | R. Kobos | R. Van Rampelbergh | R. V. Rampelbergh | Christopher Chiu